Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $456 from $476 and keeps an Equal ...

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 42% Undervalued Vertex Pharmaceuticals' estimated fair value is US$708 based on 2 Stage Free Cash Flow to ...

Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, was recognized on Built In’s 50 Best Remote Large Places to Work and 100 Best Remote Places to ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

The announcement comes directly from Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated, with the signatory on the report being Jonathan Biller, the Executive Vice President and Chief Legal Officer ...

Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall. Vertex will continue testing ...

Vertex's Phase 2 study of suzetrigine met its primary endpoint, reducing pain on the NPRS by -2.02 at Week 12. Post-hoc analysis revealed variability in placebo response, highlighting trial design ...

Vertex Pharmaceuticals’ (NASDAQ:VRTX) investigational non-opioid drug, suzetrigine, has met the primary endpoint in a mid-stage study in people with painful lumbosacral radiculopathy (LSR ...

Among the distinguished recipients, Trinasolar’s Vertex S+ Black Series has once again claimed a prestigious position. This is the second time the series has received this accolade, following ...